Systemic sclerosis (SSc) is a chronic connective tissue disease with autoimmune background, characterized by vascular damage and consequent ischemic-reperfusion injury and multiorgan fibrosis. B cell phenotypic alterations and activation accompanied by the production of disease-specific autoantibodies, secretion of pro-inflammatory and pro-fibrotic cytokines and direct cooperation with fibroblasts and T cells contribute to the development of SSc. The anti-CD20 monoclonal antibody therapy seems to show some clinical efficacy in SSc further emphasizing the importance of B cells in the development of the disease. Detailed analysis of B lymphocytes of patients with different forms and stages of systemic sclerosis could contribute to the better understanding of the pathomechanism of the disease, and may identify new biomarkers for assessment of disease activity, determination of disease subsets, and prediction of prognosis. The results of these studies may also be directly exploited in the development of new diagnostic tools and therapeutic approaches targeting pathological B cells that could advance medical treatment and recovery of the affected patients.
felvehető hallgatók száma: 1
Jelentkezési határidő: 2024-05-16
2024. IV. 17. ODT ülés Az ODT következő ülésére 2024. június 14-én, pénteken 10.00 órakor kerül sor a Semmelweis Egyetem Szenátusi termében (Bp. Üllői út 26. I. emelet).
Bejelentkezés
